trial · primary record
BI 1823911
Solid Tumors, KRAS Mutation
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2026-12-27 |
| Primary endpoint | Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination |
| Registry ID | NCT04973163 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:00.219Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04973163
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.